EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Rationale and design of a study on D-dimer use to stratify patients after a first unprovoked venous thromboembolism for their risk of recurrence: extended low-dose Apixaban given only to patients with positive D-dimer results

Gualtiero Palareti, Paolo Prandoni, Cristina Legnani, Emilia Antonucci, Serena Zorzi, Alberto Tosetto, Lorenza Bertù, Sophie Testa, Vittorio Pengo, Walter Ageno, Ida Martinelli, Benilde Cosmi und 2 weitere

Bleeding, Thrombosis and Vascular Biology · 2022

DOI: 10.4081/btvb.2022.10 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bleeding, Thrombosis and Vascular Biology, 2022. Verfasst von Gualtiero Palareti und 13 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Optimal duration of anticoagulation in patients with a first venous thromboembolism (VTE) is still uncertain. Extended anticoagulant treatment beyond the first 3 to 6 months is recommended in patients with unprovoked VTE for their high risk of recurrence, provided the risk of bleeding during anticoagulation is not high. Recent meta-analyses indicated that only one-third of these patients have a recurrence 10 years after anticoagulation is stopped, whereas the risk of major bleeding is consistent and persistent during anticoagulation. We designed the prospective, multicenter Apidulcis study to test whether serial D-dimer measurements, using commercial assays with predefined sex-specific cutoffs (350 ng/mL and 500 ng/mL for men and women, respectively, for assays expressing results as fibrinogen equivalent units), may be useful to stratify patients for the risk of recurrence. Those presenting positive D-dimer results, considered at higher risk, will receive low dose Apixaban, 2.5 mg tablets BID for 18 months, whereas those with persistently negative D-dimer results, considered at lower risk, will remain without anticoagulant treatment. Outpatients with a first VTE (unprovoked or associated with weak risk factors), aged 18 to 74 years, who have already received anticoagulation for at least 12 months are eligible for the study.

Zitieren

APA

Palareti, G., Prandoni, P., Legnani, C., Antonucci, E., Zorzi, S., Tosetto, A., Bertù, L., Testa, S., Pengo, V., Ageno, W., Martinelli, I., Cosmi, B., Bucherini, E., & Poli, D. (2022). Rationale and design of a study on D-dimer use to stratify patients after a first unprovoked venous thromboembolism for their risk of recurrence: extended low-dose Apixaban given only to patients with positive D-dimer results. Bleeding, Thrombosis and Vascular Biology. https://doi.org/10.4081/btvb.2022.10

Vancouver

Palareti G, Prandoni P, Legnani C, Antonucci E, Zorzi S, Tosetto A, et al. Rationale and design of a study on D-dimer use to stratify patients after a first unprovoked venous thromboembolism for their risk of recurrence: extended low-dose Apixaban given only to patients with positive D-dimer results. Bleeding, Thrombosis and Vascular Biology. 2022. doi:10.4081/btvb.2022.10

BibTeX
@article{Palareti2022,
  author = {Palareti, Gualtiero and Prandoni, Paolo and Legnani, Cristina and Antonucci, Emilia and Zorzi, Serena and Tosetto, Alberto and Bertù, Lorenza and Testa, Sophie and Pengo, Vittorio and Ageno, Walter and Martinelli, Ida and Cosmi, Benilde and Bucherini, Eugenio and Poli, Daniela},
  title = {Rationale and design of a study on D-dimer use to stratify patients after a first unprovoked venous thromboembolism for their risk of recurrence: extended low-dose Apixaban given only to patients with positive D-dimer results},
  journal = {Bleeding, Thrombosis and Vascular Biology},
  year = {2022},
  doi = {10.4081/btvb.2022.10}
}
Kostenlos starten →